EpilepsyNCT07449845
Quality of Life Assessment in Patients With Epilepsy Using QOLIE-31
An observational study of Epilepsy, run by Saglik Bilimleri Universitesi at 1 site in Turkey (Türkiye).
Trial summary
This observational study aims to assess quality of life in individuals with epilepsy using the Quality of Life in Epilepsy Inventory (QOLIE-31). A total of 90 adult patients with a clinical diagnosis of epilepsy will be evaluated through standardized questionnaires administered during routine clinical visits. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Epilepsy
- How many people
- 90 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Feb 2026to 1 Apr 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients with a confirmed diagnosis of epilepsy who are receiving routine care at a neurology clinic and are able to complete the QOLIE-31 questionnaire will be included. The population reflects individuals with varying clinical characteristics encountered in everyday epilepsy practice.
Who may be able to join
- Age ≥18 years
- Clinical diagnosis of epilepsy confirmed by a neurologist
- Ability to complete QOLIE-31 questionnaire
- Informed consent provided
Who cannot join
- Severe cognitive impairment
- Acute medical or psychiatric condition interfering with participation
- Inability to understand questionnaire
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Saglik Bilimleri University Izmir Faculty of Medicine Department of Neurology
Izmir
About this study
Official title: Assessment of Health-Related Quality of Life in Adults With Epilepsy Using the Quality of Life in Epilepsy Inventory (QOLIE-31): A Cross-Sectional Observational Study
This observational study aims to assess quality of life in individuals with epilepsy using the Quality of Life in Epilepsy Inventory (QOLIE-31). A total of 90 adult patients with a clinical diagnosis of epilepsy will be evaluated through standardized questionnaires administered during routine clinical visits. The study seeks to characterize patient-reported quality of life across multiple domains and to provide insight into factors affecting daily functioning and well-being in people living with epilepsy.
- Conditions
- Epilepsy
- Medical subject headings
- Epilepsy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| epilepsy | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Quality of life measured by QOLIE-31 total score
The Quality of Life in Epilepsy Inventory-31 is a validated epilepsy-specific quality of life scale consisting of 31 items. The total score ranges from 0 to 100. Higher scores indicate better health-related quality of life.
Measured: At study enrollment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Mar 2026
- Study start1 Feb 2026
- Primary completion1 Mar 2026
- Study completion1 Apr 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for EpilepsyStudies of the same condition, open and under way.
- More trials run by Saglik Bilimleri UniversitesiThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 90 participants (actual)
Sponsor and investigators
- Lead sponsor
- Saglik Bilimleri Universitesi
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07449845
- Sponsor's protocol ID
- 2026/01-26
- Status last verified
- Feb 2026
- First submitted
- 26 Feb 2026
- Last updated
- 30 Apr 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment of Health-Related Quality of Life in Adults With Epilepsy Using the Quality of Life in Epilepsy Inventory (QOLIE-31): A Cross-Sectional Observational Study
- ClinicalTrials.gov ID
- NCT07449845
- Acronym / sponsor ID
- 2026/01-26
- Conditions
- Epilepsy
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 90 participants (actual)
- Lead sponsor
- Saglik Bilimleri UniversitesiUniversity, hospital or other
- Study start
- 1 Feb 2026 (actual)
- Primary completion
- 1 Mar 2026 (actual)
- Study completion
- 1 Apr 2026 (actual)
- First posted
- 4 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This observational study aims to assess quality of life in individuals with epilepsy using the Quality of Life in Epilepsy Inventory (QOLIE-31). A total of 90 adult patients with a clinical diagnosis of epilepsy will be evaluated through standardized questionnaires administered during routine clinical visits. The study seeks to characterize patient-reported quality of life across multiple domains and to provide insight into factors affecting daily functioning and well-being in people living with epilepsy.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| epilepsy | – | – |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients with a confirmed diagnosis of epilepsy who are receiving routine care at a neurology clinic and are able to complete the QOLIE-31 questionnaire will be included. The population reflects individuals with varying clinical characteristics encountered in everyday epilepsy practice.
Key inclusion criteria (4 listed)
- Age ≥18 years
- Clinical diagnosis of epilepsy confirmed by a neurologist
- Ability to complete QOLIE-31 questionnaire
- Informed consent provided
Key exclusion criteria (3 listed)
- Severe cognitive impairment
- Acute medical or psychiatric condition interfering with participation
- Inability to understand questionnaire
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Quality of life measured by QOLIE-31 total score
Time frame: At study enrollment
The Quality of Life in Epilepsy Inventory-31 is a validated epilepsy-specific quality of life scale consisting of 31 items. The total score ranges from 0 to 100. Higher scores indicate better health-related quality of life.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Apr 2026.
- Individual participant dataSharing planned: No
Related trials for Epilepsy
Not yet recruiting
Clinical Trial of SEEG for Drug-resistant Epilepsy
Drug-Resistant Epilepsy
RecruitingPhase 3
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
Seizures, Lennox Gastaut Syndrome
RecruitingPhase 3
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
Focal Seizure, Epilepsy
Active, not recruitingObservational study
Transforming Research and Clinical Knowledge in Traumatic Brain Injury Epileptogenesis Project (TRACK-TBI EPI)
Traumatic Brain Injury, Post-traumatic Epilepsy
RecruitingPhase 3
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
Focal Seizure, Epilepsy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Epilepsy, run by Saglik Bilimleri Universitesi at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Quality of life measured by QOLIE-31 total score (time frame: At study enrollment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Apr 2026.